OTCMKTS:BIOAF Bioasis Technologies (BIOAF) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free BIOAF Stock Alerts $0.0069 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.0069▼$0.009250-Day Range$0.0032▼$0.007552-Week Range$0.0015▼$0.0186Volume15,434 shsAverage Volume80,280 shsMarket Capitalization$547,929.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Bioasis Technologies alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Bioasis Technologies Stock (OTCMKTS:BIOAF)Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Read More BIOAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOAF Stock News HeadlinesJanuary 9, 2024 | morningstar.comBioasis Technologies Inc 107August 1, 2023 | investing.combiOasis Technologies Inc (BTI) Earnings Dates & ReportsMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. June 27, 2023 | benzinga.comShort Volatility Alert: Bioasis Tech IncJune 22, 2023 | chron.comNew Haven biotech company suspending operations after failed mergerJune 21, 2023 | finanznachrichten.deBioasis Technologies Inc.: Bioasis Provides Corporate Update and Announces Suspension of OperationsMarch 23, 2023 | finance.yahoo.comBioasis Provides Update on Business OperationsJanuary 19, 2023 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022March 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. December 16, 2022 | chron.comNew Haven-based biotech company signs $5.42 million agreement to merge with British companyDecember 13, 2022 | marketwatch.comMidatech Pharma Shares Fall on Bioasis Technologies Buy, Plan to Cancel AIM ListingDecember 13, 2022 | finance.yahoo.com/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - ResumptionsOctober 29, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022August 8, 2022 | finance.yahoo.comBioasis Technologies Inc. Announces Stock Option GrantsJune 16, 2022 | finance.yahoo.comBioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsApril 26, 2022 | finance.yahoo.comBIOAF: Collaboration Arrangement with JanssenApril 11, 2022 | seekingalpha.comBioasis enters into research collaboration with Janssen for its xB3 platformApril 11, 2022 | finance.yahoo.comBioasis Enters Into Research Collaboration With JanssenJanuary 31, 2022 | finance.yahoo.comBIOAF: Third Quarter ResultsJanuary 20, 2022 | sfgate.comBiOasis: Fiscal Q3 Earnings SnapshotJanuary 20, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021January 16, 2022 | nasdaq.comBioasis Technologies Inc (BIOAF)November 3, 2021 | finance.yahoo.comBIOAF: Second Quarter UpdateOctober 28, 2021 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021August 18, 2021 | apnews.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business ...August 18, 2021 | financialpost.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development AdvisorAugust 10, 2021 | apnews.comBioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion ...See More Headlines Receive BIOAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today3/18/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drugs, proprietaries, & sundries Sub-IndustryN/A Current SymbolOTCMKTS:BIOAF CUSIPN/A CIKN/A Webwww.bioasis.us Phone(203) 533-7082FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$30,000.00 Price / Sales18.53 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares79,410,000Free FloatN/AMarket Cap$555,870.00 OptionableNot Optionable Beta0.91 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Deborah Ann Rathjen B.Sc. (Hons.) (Age 66)FTSE, M.A.I.C.D., Ph.D., Q.C., Executive Chairman, CEO & President Comp: $155.18kMr. David P. Jenkins (Age 62)Chief Financial Officer Comp: $93.11kMr. Graeme DickDirector of Investor RelationsMr. Aaron EltonDirector of MarketingDr. Mei Mei TianVP & Head of External ResearchKey CompetitorsRevelation BiosciencesNASDAQ:REVBGRI BioNASDAQ:GRIZicixOTCMKTS:ZICXH-CYTEOTCMKTS:HCYTDKayaOTCMKTS:KAYSDView All Competitors BIOAF Stock Analysis - Frequently Asked Questions How have BIOAF shares performed in 2024? Bioasis Technologies' stock was trading at $0.0047 at the beginning of 2024. Since then, BIOAF shares have increased by 46.8% and is now trading at $0.0069. View the best growth stocks for 2024 here. How were Bioasis Technologies' earnings last quarter? Bioasis Technologies Inc. (OTCMKTS:BIOAF) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). How do I buy shares of Bioasis Technologies? Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOAF) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioasis Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.